Evidence map›Paper›PMID 35269701›Full record

ArticleInternational journal of molecular sciences2022

Activation of Mast-Cell-Derived Chymase in the Lacrimal Glands of Patients with IgG4-Related Ophthalmic Disease.

Yasushi Fujita, Denan Jin, Masashi Mimura, Yohei Sato, Shinji Takai, Teruyo Kida

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yasushi FujitaDepartment of Ophthalmology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Denan JinDepartment of Innovative Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.ORCID 0000-0002-5820-8168
Masashi MimuraDepartment of Ophthalmology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Yohei SatoDepartment of Ophthalmology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Shinji TakaiDepartment of Innovative Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Teruyo KidaDepartment of Ophthalmology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Osaka University of Pharmaceutical Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this present study was to investigate the distribution and expression of chymase in the lacrimal glands (LGs) of patients afflicted with IgG4-related ophthalmic disease (IgG4-ROD). LGs from patients with severe canalicular obstruction were considered the control group. Toluidine blue staining confirmed a significant increase in the number of mast cells in the LGs obtained from the IgG4-ROD patients. In addition, immunostaining of serial sections from the LGs showed a significant increase in the number of chymase-positive cells and tryptase-positive cells in the IgG4-ROD LGs compared to the normal control LGs. The mRNA expression of chymase, tryptase, TGF-β1, and collagen-I tended to increase in the IgG4-ROD LGs. Immunostaining of vimentin and α-smooth muscle actin (α-SMA) showed that myofibroblasts were the main cellular components in severely fibrotic regions of LGs in patients with IgG4-ROD. Linear regression analyses on the number of mast cells, chymase-positive cells, and tryptase-positive cells revealed significant positive correlations between those respective cells. Our findings suggest that chymase may play a role in the fibrotic disorder of IgG4-ROD LGs through the regulation of TGF-β1 activation and collagen-I deposition, and that it may be a therapeutic target for patients afflicted with IgG4-ROD.

Indexed as

Immunoglobulin G4-Related DiseaseLacrimal ApparatusChymasesCollagen Type IFibrosisHumansImmunoglobulin GMast CellsTransforming Growth Factor beta1TryptasesChymasesCollagen Type IImmunoglobulin GTransforming Growth Factor beta1TryptaseschymaseIgG4-related ophthalmic disease (IgG4-ROD)lacrimal glands (LGs)mast cells (MCs)transforming growth factor-β1 (TGF-β1)

Identifiers

PMID35269701
PMCPMC8910072
OpenAlexW4214557490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.